Breathe Well Live Well
|
FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular Events
Monthly Prescribing Reference The Food and Drug Administration (FDA) is warning about a slightly increased risk of cardiovascular and cerebrovascular events among patients being treated with Xolair (omalizumab; Genentech and Novartis) for asthma compared to those not treated with … Xolair (omalizumab): Drug Safety Communication – Slightly Elevated Risk of … |
View full post on asthma – Google News
|
Research and Markets: PharmaPoint: Asthma – 5EU Drug Forecast and Market …
Rock Hill Herald (press release) The relatively slow growth of the German market compared with the French, Spanish, and UK markets is attributable to the slightly decreasing prevalence of asthma in this country over the forecast period. Advair's active patent on the Diskus delivery … |
View full post on asthma – Google News
|
Asthma Drug Market 2023 Forecasts: US, 5EU & Japan Industry Analysis
MarketWatch According to Asthma – 5EU Drug Forecast and Market Analysis to 2023 research report covering the UK, France, Italy, Spain, Germany, the 2013 base-year market sales of asthma products in France were $918m.The relatively slow growth of the German … Fostair Asthma Market Forecast Analysis in recent report |
View full post on asthma – Google News
|
Malaria drug shows promise treating asthma
Futurity: Research News A malaria drug derived from the artemisia plant might offer an alternative way to treat asthma. The drug, called artesunate, works like dexamethasone, the most potent steroid currently available. Like the steroid, artesunate suppresses airway … |
View full post on asthma – Google News
|
Teva Pharmaceuticals New Drug Aims to Reduce Asthma Attacks
Motley Fool Asthma is one of the planet's more common diseases. It affects roughly 300 million people and despite the availability of treatment designed to help reduce asthma attacks, millions of people's asthma is poorly controlled. As a result, a host of … |
View full post on asthma – Google News
Reuters India |
A respiratory expert undermines GSK's case for new asthma drug mepolizumab
FierceBiotech Investigators for GlaxoSmithKline ($GSK) detailed their promising Phase III data for the IL-5 biologic mepolizumab in asthma today, noting that the injectable halved the rate of exacerbations among a group of patients with uncontrolled cases of the … UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs |
View full post on asthma – Google News
|
Teva's Asthma Drug 'Significantly' Improves Lung Function In Phase 3 Trials
NASDAQ (RTTNews.com) – Teva Pharmaceutical Industries Ltd. ( TEVA ) Monday said asthma patients with elevated eosinophils showed significant improvement in lung function and asthma control after being treated with reslizumab in final-stage studies of the anti … |
View full post on asthma – Google News
Globes |
Teva's well-traveled asthma drug comes through in Phase III
FierceBiotech The drug, which works by blocking the interleukin-5 pathway, met its primary endpoints in two Phase III studies on patients with inadequately controlled asthma and elevated levels of inflammatory white blood cells, Teva said. In 12-month data from more … Teva finds positive results in advanced trials for asthma drug Teva's Reslizumab Shows Reduction In Asthma Exacerbations In Clinical Studies Teva stakes its claim to the asthma antibody market |
View full post on asthma – Google News
Economic Times |
Cipla Ltd launches copy of GSK's top asthma drug in Germany, Sweden
Economic Times MUMBAI: Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product. Cipla's drug will be marketed under … |
View full post on asthma – Google News
|
Asthma market to reach $23.1 billion due to targeted biologics
Drug Store News LONDON — The asthma treatment market value will grow from approximately $15.9 billion in 2013 across eight major countries (the United States, United Kingdom, France, Germany, Spain, Italy, Japan and Australia) to $23.1 billion by 2023, according to … |
View full post on asthma – Google News